Paying users zone. Data is hidden behind .
Get 1-month access to Bristol-Myers Squibb Co. for $17.99, or
get full access to the entire website for at least 3 months from $49.99.
We accept:
This is a one-time payment. There is no automatic renewal.
Bristol-Myers Squibb Co. (BMY)
Analysis of Liquidity Ratios
Beginner level
Liquidity ratios measure the company’s ability to meet its short-term obligations.
Liquidity Ratios (Summary)
Bristol-Myers Squibb Co., liquidity ratios
Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
---|---|---|---|---|---|---|
Current ratio | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Quick ratio | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Cash ratio | ![]() |
![]() |
![]() |
![]() |
![]() |
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
Liquidity ratio | Description | The company |
---|---|---|
Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | Bristol-Myers Squibb Co.’s current ratio improved from 2016 to 2017 and from 2017 to 2018. |
Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | Bristol-Myers Squibb Co.’s quick ratio improved from 2016 to 2017 and from 2017 to 2018. |
Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | Bristol-Myers Squibb Co.’s cash ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 exceeding 2016 level. |
Current Ratio
Bristol-Myers Squibb Co., current ratio calculation, comparison to benchmarks
Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Current assets | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Current liabilities | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Liquidity Ratio | ||||||
Current ratio1 | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Benchmarks | ||||||
Current Ratio, Competitors2 | ||||||
Abbott Laboratories | ![]() |
![]() |
![]() |
![]() |
![]() |
|
AbbVie Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Allergan PLC | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Amgen Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Biogen Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Eli Lilly & Co. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Gilead Sciences Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Johnson & Johnson | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Merck & Co. Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Pfizer Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Regeneron Pharmaceuticals Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Current Ratio, Sector | ||||||
Pharmaceuticals & Biotechnology | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Current Ratio, Industry | ||||||
Health Care | ![]() |
![]() |
![]() |
![]() |
![]() |
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
1 2018 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷
=
2 Click competitor name to see calculations.
Liquidity ratio | Description | The company |
---|---|---|
Current ratio | A liquidity ratio calculated as current assets divided by current liabilities. | Bristol-Myers Squibb Co.’s current ratio improved from 2016 to 2017 and from 2017 to 2018. |
Quick Ratio
Bristol-Myers Squibb Co., quick ratio calculation, comparison to benchmarks
Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Cash and cash equivalents | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Marketable securities | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Net trade receivables | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Alliance receivables | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Royalties, VAT and other | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Total quick assets | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Current liabilities | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Liquidity Ratio | ||||||
Quick ratio1 | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Benchmarks | ||||||
Quick Ratio, Competitors2 | ||||||
Abbott Laboratories | ![]() |
![]() |
![]() |
![]() |
![]() |
|
AbbVie Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Allergan PLC | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Amgen Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Biogen Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Eli Lilly & Co. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Gilead Sciences Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Johnson & Johnson | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Merck & Co. Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Pfizer Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Regeneron Pharmaceuticals Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Quick Ratio, Sector | ||||||
Pharmaceuticals & Biotechnology | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Quick Ratio, Industry | ||||||
Health Care | ![]() |
![]() |
![]() |
![]() |
![]() |
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
1 2018 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷
=
2 Click competitor name to see calculations.
Liquidity ratio | Description | The company |
---|---|---|
Quick ratio | A liquidity ratio calculated as (cash plus short-term marketable investments plus receivables) divided by current liabilities. | Bristol-Myers Squibb Co.’s quick ratio improved from 2016 to 2017 and from 2017 to 2018. |
Cash Ratio
Bristol-Myers Squibb Co., cash ratio calculation, comparison to benchmarks
Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||
Cash and cash equivalents | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Marketable securities | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Total cash assets | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Current liabilities | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Liquidity Ratio | ||||||
Cash ratio1 | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Benchmarks | ||||||
Cash Ratio, Competitors2 | ||||||
Abbott Laboratories | ![]() |
![]() |
![]() |
![]() |
![]() |
|
AbbVie Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Allergan PLC | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Amgen Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Biogen Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Eli Lilly & Co. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Gilead Sciences Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Johnson & Johnson | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Merck & Co. Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Pfizer Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Regeneron Pharmaceuticals Inc. | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Cash Ratio, Sector | ||||||
Pharmaceuticals & Biotechnology | ![]() |
![]() |
![]() |
![]() |
![]() |
|
Cash Ratio, Industry | ||||||
Health Care | ![]() |
![]() |
![]() |
![]() |
![]() |
Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).
1 2018 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷
=
2 Click competitor name to see calculations.
Liquidity ratio | Description | The company |
---|---|---|
Cash ratio | A liquidity ratio calculated as (cash plus short-term marketable investments) divided by current liabilities. | Bristol-Myers Squibb Co.’s cash ratio deteriorated from 2016 to 2017 but then improved from 2017 to 2018 exceeding 2016 level. |